Research programme: HDL-related therapeutics - Esperion/University of Michigan

Drug Profile

Research programme: HDL-related therapeutics - Esperion/University of Michigan

Alternative Names: Paraoxonase research programme - Esperion Therapeutics/University of Michigan; Research programme: dyslipidaemia therapies - Pfizer/University of Michigan

Latest Information Update: 30 Apr 2007

Price : $50

At a glance

  • Originator University of Michigan
  • Developer Esperion Therapeutics; University of Michigan
  • Class Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Septic shock

Most Recent Events

  • 30 Apr 2007 NTTC project; made disc
  • 16 Feb 2004 Esperion Therapeutics has been acquired by and merged into Pfizer
  • 01 Feb 2001 Preclinical development for Sepsis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top